Thymalin

1. Overview

Thymalin is a polypeptide complex originally isolated from the thymus gland of young calves, developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad (now Saint Petersburg), Russia. It was the first in a class of compounds Khavinson termed "peptide bioregulators" -- short-chain peptides proposed to restore organ function through direct interaction with gene regulatory elements [8] [23].

The preparation contains a mixture of low-molecular-weight peptides (up to 10 kDa), with three principal bioactive components identified through reversed-phase HPLC: the dipeptide L-Glu-L-Trp (EW, later synthesized independently as the drug Thymogen), the dipeptide Lys-Glu (KE, marketed as Vilon), and the tripeptide Glu-Asp-Pro (EDP, known as Crystagen) [5] [7]. The most pharmacologically characterized of these is the EW dipeptide, with molecular formula C16H19N3O5 and molecular weight 333.34 g/mol.

Thymalin was first approved for clinical use in the USSR in 1982 for immunodeficiency states and has remained in the Russian pharmacopeia since then (current registration LS-000267). It is not approved by the FDA, EMA, or other Western regulatory agencies. While the body of published research spans over four decades and encompasses hundreds of papers, the overwhelming majority originates from Khavinson's group and affiliated institutions, and independent replication by Western laboratories remains limited [9].

Type

Polypeptide complex (thymic extract) containing dipeptides EW, KE, and tripeptide EDP

Key Active Component

L-Glu-L-Trp (EW dipeptide); MW 333.34 g/mol; C16H19N3O5

Source

Bovine calf thymus gland extract

Routes Studied

Intramuscular, subcutaneous

Russian Approval

Approved (LS-000267, 2010 re-registration; clinical use since 1982)

FDA/EMA Status

Not approved by any Western regulatory agency

2. Molecular Composition

Thymalin (Extract)

Thymalin is produced through acid hydrolysis of bovine calf thymus tissue followed by ultrafiltration to isolate peptides below 10 kDa. The resulting mixture is lyophilized into a sterile powder for reconstitution and intramuscular injection [5]. Unlike single-entity pharmaceuticals, Thymalin is a multi-component preparation containing numerous peptide fractions, though its biological activity has been attributed primarily to three identified short peptides.

Key Active Peptides

The three principal active components isolated from Thymalin are:

• EW (Glu-Trp / Thymogen): Dipeptide with MW 333.34 g/mol. Activates T-cell differentiation, modulates cyclic nucleotide balance (cAMP/cGMP), and enhances neutrophil chemotaxis and phagocytosis. Separately approved in Russia as the synthetic drug Thymogen [3] [7] [15].
• KE (Lys-Glu / Vilon): Dipeptide that demonstrates selective binding to TCGA DNA sequences and regulates expression of genes involved in immune cell proliferation [6] [22].
• EDP (Glu-Asp-Pro / Crystagen): Tripeptide associated with normalization of immunograms in clinical settings, with reported efficacy of 82% versus 56% in controls [5].

3. Mechanism of Action

Thymalin operates through several interconnected immunological and molecular pathways:

T-Cell Maturation and Immune Reconstitution

Thymalin peptides interact with thymic epithelial cells, promoting thymocyte selection and maturation. The preparation normalizes the number and ratio of T and B lymphocytes and their subpopulations, increases their functional activity, and enhances phagocytosis [5]. Specific effects include upregulation of major histocompatibility complex molecules on thymic epithelial cells, enhanced output of mature naive T cells, and restoration of CD4/CD8 T-cell ratios toward values characteristic of younger individuals [2] [4].

Peptide-DNA Interaction (Khavinson Bioregulator Theory)

The central theoretical framework advanced by Khavinson proposes that short peptides (2-7 amino acids) can bypass cell membrane receptors, penetrate into cell nuclei, and interact directly with double-stranded DNA and histone proteins [6]. According to this model:

• The EW peptide shows energetically favorable binding to histone H1/3, altering chromatin conformation and gene accessibility [5] [14].
• The KE peptide demonstrates selective binding to TCGA DNA sequence motifs in gene promoter regions [6].
• These interactions modulate transcription of genes involved in immune function, heat-shock protein synthesis, cytokine production (IL-3, IL-4, IL-5, IL-6, IL-10, IL-17A, TNF-alpha), and fibrinolysis [5] [10].

This theory remains controversial in mainstream molecular biology, as the concept of di- and tripeptides acting as transcription factor-like regulators through direct DNA binding has not been independently validated outside Khavinson's research network [9].

Cytokine and Inflammatory Modulation

In the THP-1 monocyte/macrophage cell line, constituent peptides of Thymalin regulated proliferative activity and inflammatory pathways, modulating the balance between pro-inflammatory and anti-inflammatory cytokine expression [10]. In COVID-19 patients, Thymalin reduced IL-6 levels by 6.5-fold and C-reactive protein by 3.3-fold compared to standard therapy [4].

Epigenetic Effects

Studies have reported that Thymalin-derived peptides can influence chromatin structure, promoting an increase in transcriptionally active euchromatin and a decrease in heterochromatin in blood lymphocytes of elderly individuals [6] [14]. The KE peptide has been reported to normalize telomere length in PHA-stimulated lymphocytes across different age groups [9].

4. Development History

The development of Thymalin traces back to the early 1970s, when Vladimir Khavinson and Vyacheslav Morozov, then colonels at the Military Medical Academy in Leningrad, were commissioned by the Soviet Ministry of Defense to develop treatments for soldiers exposed to radiation, chemical agents, and severe injuries [7] [23].

Thymalin was isolated from calf thymus tissue in 1974. Clinical testing began shortly after, and the preparation was approved by the USSR Pharmacological Committee for clinical use in 1977, with formal drug registration completed by 1982. It represented the first in what would become a series of over 20 peptide bioregulator preparations extracted from various organs by Khavinson's group [23].

In 1992, Khavinson founded the Saint Petersburg Institute of Bioregulation and Gerontology, which became part of the Russian Academy of Medical Sciences in 2001. The institute has served as the primary center for peptide bioregulator research, generating over 700 published papers and more than 200 patents across four decades [8] [9].

The synthetic dipeptide EW (Thymogen) was later isolated from Thymalin via RP-HPLC and synthesized as a standalone pharmaceutical, receiving separate regulatory approval in Russia. This represented a transition from complex thymic extracts to defined synthetic peptides in Khavinson's research program [7] [15].

5. Researched Applications

Immune Reconstitution in Elderly Populations

The most extensive clinical data for Thymalin involves its use in elderly patients with age-related immunodeficiency. The thymus undergoes progressive involution beginning at puberty, with the majority of functional tissue replaced by adipose tissue by age 60-70, directly correlating with decline in naive T-cell output and weakened immune surveillance [2] [5].

In a landmark observational study, 266 elderly participants (age 60 and older) at the Saint Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences received Thymalin, Epithalamin, or both for 2-3 years and were followed for 6-8 years. Thymalin treatment was associated with normalization of cardiovascular, endocrine, immune, and nervous system indices, a 2.0-2.4-fold decrease in acute respiratory disease incidence, and a 2.0-2.1-fold decrease in mortality compared to controls [1] [2].

COVID-19 in Elderly Patients

A prospective, randomized, single-blind controlled trial at Chita State Medical Academy Hospital studied 80 elderly patients with severe COVID-19 pneumonia. Patients receiving Thymalin (10 mg/day IM for 10 days) in addition to standard therapy showed significantly improved outcomes compared to controls [4]:

• Hospital mortality: 19.4% versus 40.9% (p=0.039)
• Lymphocyte recovery: 92% increase versus minimal change in controls
• Clinical improvement rate: 80.5% versus 59% (p=0.039)
• Time to recovery: 7.36 days versus 10.78 days (p=0.002)
• IL-6 reduction: 6.5-fold versus no significant change

Anti-Aging and Longevity

In the longest-term human data, a subgroup of patients receiving combined Thymalin plus Epithalamin annually for 6 years demonstrated a 4.1-fold reduction in mortality compared to controls [1]. While these findings are striking, the study was observational rather than randomized, and allocation to treatment groups was not blinded [9].

Anti-Carcinogenesis (Animal Data)

In a 12-month study, 76 female outbred rats received subcutaneous injections of synthetic L-Glu-L-Trp (5 mcg/rat, 5 times weekly). Compared to saline controls, treated animals showed total tumor incidence reduced 1.5-fold, malignant tumor incidence reduced 1.7-fold, and hematopoietic malignancy incidence reduced 3.4-fold. Treatment also slowed age-related changes as measured by estrous cycle function and body weight parameters [3].

Immunocorrection in Clinical Medicine

In Russian clinical practice, Thymalin has been used as an adjunct in treatment of acute and chronic infections, post-surgical immune restoration, immunodeficiency following chemotherapy or radiation therapy, and impaired tissue regeneration processes [5] [12].

6. Clinical Evidence

The clinical evidence for Thymalin exists primarily in Russian-language medical literature, with a smaller number of publications in international peer-reviewed journals. The evidence can be summarized by level:

Randomized Controlled Trials: One published RCT in COVID-19 patients (n=80) demonstrated significant reductions in mortality, faster lymphocyte recovery, and improved clinical outcomes [4]. A second study examined adaptive immunity in COVID-19 patients treated with Thymalin as part of complex therapy [12].

Observational/Longitudinal Studies: The principal longevity dataset involves 266 elderly patients followed for 6-8 years, with reported mortality reductions of 2.0-4.1-fold depending on treatment regimen [1] [2]. These studies were conducted at affiliated Russian and Ukrainian institutions and have not been replicated independently.

Animal Studies: Multiple rodent studies from Khavinson's group and collaborator V.N. Anisimov demonstrate anti-aging and anti-tumor effects of the EW dipeptide and Thymalin extract [3] [9].

In Vitro Studies: Thymalin and its constituent peptides have been studied in organotypic spleen tissue cultures, where they increased growth zone indices by 20-50%, stimulated proliferation, and reduced apoptosis by 29-42% [5] [10].

A critical limitation is that virtually all published clinical data originates from Khavinson's institute and affiliated centers. No large-scale, multicenter, double-blind Phase III trials conducted by independent research groups have been identified.

7. Dosing in Published Research

The following doses have been reported in published research. These are not recommendations and should not be interpreted as therapeutic guidance.

In Russian clinical practice, the standard protocol involves 10 mg Thymalin reconstituted in 0.9% NaCl administered intramuscularly once daily for 5-10 days, with courses repeated at intervals of several months to annually [5] [4]. Animal studies of the synthetic EW dipeptide used substantially lower doses (5 mcg/rat) given over extended periods [3].

8. Comparison with Other Thymic Peptides

Thymalin belongs to a broader family of thymus-derived peptides that have been investigated as immunomodulators. Key comparisons include:

Thymosin Alpha-1 (Thymalfasin)

Thymosin alpha-1 is a 28-amino acid peptide first isolated from thymosin fraction 5 in 1977. Unlike Thymalin, it is a well-defined single peptide with established receptor-mediated signaling through Toll-like receptors (TLR2, TLR9) and dendritic cell activation [16] [17] [21]. Thymosin alpha-1 has been approved in over 35 countries (marketed as Zadaxin) for hepatitis B and as an immune adjuvant, and has undergone extensive independent clinical testing. It represents the most clinically validated thymic peptide globally.

Thymulin (FTS-Zn)

Thymulin is a zinc-dependent nonapeptide (9 amino acids) produced by thymic epithelial cells. Its biological activity requires conjugation with a zinc ion, and its circulating levels decline with age in parallel with thymic involution [18] [20]. Thymulin primarily acts as a neuroendocrine-immune modulator and has been less developed clinically than thymosin alpha-1.

Thymopentin (TP-5)

Thymopentin is a synthetic pentapeptide corresponding to residues 32-36 of the thymic hormone thymopoietin. It enhances T-cell differentiation and has been studied in burn patients and immunodeficiency, with improved survival rates reported in animal models [19].

Key Distinctions

Thymalin differs from these agents in being a multi-component extract rather than a defined single peptide. While thymosin alpha-1 acts through conventional cell-surface receptor signaling, Khavinson's bioregulator theory proposes that Thymalin's short peptide components act through direct intranuclear DNA binding -- a fundamentally different and less validated mechanism [6] [7]. Additionally, thymosin alpha-1 has extensive Western clinical trial data and broad international regulatory approval, whereas Thymalin's approval is limited to Russia and former Soviet states.

9. Safety and Side Effects

Thymalin has been described as having an excellent safety profile based on over 40 years of clinical use in Russia. Published literature consistently characterizes it as "practically non-toxic" with minimal reported side effects [5] [7].

In the COVID-19 RCT (n=80), no adverse events attributable to Thymalin were documented [4]. Long-term observational studies in elderly populations (6-8 years follow-up) similarly reported no significant safety concerns [1] [2]. In a topical application study, a zinc plus Thymalin formulation showed no adverse systemic effects or local reactions over 3,300 cumulative treatment days.

However, several important caveats apply:

• No systematic toxicology studies meeting current ICH/FDA regulatory standards have been published.
• Safety data come predominantly from the same research group that developed the drug, creating potential reporting bias.
• As with other immunostimulatory agents, theoretical concerns exist regarding use in patients with autoimmune conditions, organ transplant recipients on immunosuppressants, or individuals with undiagnosed malignancies.
• Long-term consequences of repeated short-peptide administration and the proposed DNA-binding mechanism have not been systematically evaluated by independent researchers.

10. Peptide Bioregulation Theory

Thymalin occupies a central position in Khavinson's broader theory of peptide bioregulation, which proposes that endogenous short peptides (2-4 amino acids) serve as tissue-specific regulators of gene expression throughout the organism [8] [23]. According to this framework:

• Each organ produces characteristic short peptides that regulate its own function through epigenetic mechanisms.
• These peptides decline with aging, contributing to organ dysfunction and age-related disease.
• Exogenous administration of organ-specific peptides can restore youthful gene expression patterns and organ function.
• The peptides act by direct interaction with DNA and chromatin rather than through conventional receptor signaling [6] [14].

This theory has generated a family of over 20 organ-specific preparations (Thymalin for thymus, Epithalamin/Epithalon for pineal gland, Cortexin for brain, Retinalamin for retina, and others) that form the basis of a clinical practice in Russia sometimes termed "peptide bioregulation therapy" [9] [23].

While the research output is extensive, the theory's core claims -- particularly that dipeptides can function as transcription regulators through direct DNA binding -- remain outside the mainstream of Western molecular biology and have not been validated by independent laboratories. The therapeutic implications, if confirmed, would represent a novel paradigm in pharmacology [9].

11. Limitations and Transparency

Several important limitations should be considered when evaluating the Thymalin literature:

• The vast majority of published research originates from the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated institutions, representing a significant concentration of evidence from a single research network [9].
• Independent replication by laboratories in Western Europe, North America, or other regions is essentially absent.
• The landmark longevity study in 266 elderly patients was observational, not randomized or blinded, with potential confounders including participant self-selection [1] [2].
• The COVID-19 RCT, while randomized and single-blind, involved a relatively small sample size (n=80) at a single center [4].
• Thymalin is a multi-component extract, making it difficult to attribute observed effects to specific molecular entities, though the synthetic EW dipeptide has been studied independently [3] [7].
• Publication bias cannot be assessed given the concentration of research within one group.
• The molecular mechanism (direct peptide-DNA binding) proposed by Khavinson represents a non-conventional model that has not gained acceptance in mainstream molecular biology [6].

12. Regulatory Status

Russia: Thymalin has been approved for clinical use since the 1980s, with current registration number LS-000267 (re-registered February 26, 2010) from the Ministry of Health of the Russian Federation. Approved indications include immunodeficiency states, adjunctive treatment during chemotherapy and radiation therapy, acute and chronic infections, and age-related immune decline [5] [23]. The synthetic derivative Thymogen (EW dipeptide) holds separate regulatory approval in Russia.

International: Thymalin is not approved by the FDA, EMA, Health Canada, TGA, or any other major Western regulatory agency. It is not listed in the United States Pharmacopeia or European Pharmacopoeia. Outside Russia and former Soviet states, it is available only through research chemical suppliers and is not a licensed pharmaceutical product.

13. Related Peptides

See also: Thymosin Alpha-1, Epithalon

14. References

1. [1] Khavinson VK, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. PubMed
2. [2] Khavinson VK, Morozov VG (2002). Geroprotective effect of thymalin and epithalamin. Adv Gerontol. PubMed
3. [3] Anisimov VN, Khavinson VK, Morozov VG (2000). Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. DOI PubMed
4. [4] Khavinson VK, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Korf HW (2021). Peptide drug Thymalin regulates immune status in severe COVID-19 older patients. Adv Gerontol. DOI PubMed
5. [5] Khavinson VK, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biol Bull Rev. DOI PubMed
6. [6] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
7. [7] Morozov VG, Khavinson VK (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. DOI PubMed
8. [8] Khavinson VK (2002). Peptides and ageing. Neuro Endocrinol Lett. PubMed
9. [9] Anisimov VN, Khavinson VK (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
10. [10] Kuznik BI, Linkova NS, Khavinson VK (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci. DOI PubMed
11. [11] Khavinson VK, Linkova NS, Kvetnoy IM (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
12. [12] Simanenkov VI, Makarenko SV, Khavinson VK (2021). Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19. Klin Med (Mosk). PubMed
13. [13] Khlystova ZS, Kalinina II, Khavinson VK (2003). Thymalin peptides and thymic differentiation in early human embryogenesis. Bull Exp Biol Med. PubMed
14. [14] Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
15. [15] Deigin VI, Antipova NV, Shubina IZ (2024). The first reciprocal activities of chiral peptide pharmaceuticals: Thymogen and Thymodepressin, as examples. Int J Mol Sci. DOI PubMed
16. [16] Tuthill C, Rios I, McBeath R (2020). Thymosin alpha 1: a comprehensive review of the literature. J Biol Regul Homeost Agents. PubMed
17. [17] Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E (2007). Thymosin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. DOI PubMed
18. [18] Bach JF (1983). Thymulin (FTS-Zn). Clin Immunol Immunopathol. PubMed
19. [19] Goldstein G, Audhya TK (1985). Thymopoietin to thymopentin: experimental studies. Surv Immunol Res. PubMed
20. [20] Lunin SM, Novoselova EG (2010). Thymus hormones as prospective anti-inflammatory agents. Expert Opin Ther Targets. DOI PubMed
21. [21] Severa M, Diotti RA, Etna MP, Rizzo F, Fionda C, Matarrese P, Garaci E, Coccia EM (2019). A reappraisal of thymosin alpha1 in cancer therapy. Front Oncol. DOI PubMed
22. [22] Markova EV, Obukhova LA, Khavinson VK (2014). Peptides regulating proliferative activity in the spleen: age-related molecular aspects. Adv Gerontol. DOI
23. [23] Khavinson VK (2020). Peptide medicines: past, present, future. Klin Med (Mosk). PubMed